公开资料显示,KH815由人源化的IgG1抗体(hRS7)组成,该抗体直接针对TROP2,结合拓扑异构酶I抑制剂(TOP1i)和RNA聚合酶II抑制剂(RNA POL IIi)。KH815的双载荷使其能够同时抑制RNA合成和诱导DNA双链断裂,具有双效协同机制。此外其还能降低P-gp和HSP70蛋白的表达,克服耐药,增加细胞对化疗药物的敏感性。辉瑞 PARP 抑制剂新适应症在华申报上市今日,CDE...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.